Factors and timing of decreased adherence to S-1 in postoperative docetaxel + S-1 therapy for gastric cancer. Investigation of synergistic effects in trials of combination therapies with ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

用于单药治疗在转移性环境中接受过至少一种内分泌治疗的不可切除或转移性HER2低表达（IHC 1+或IHC 2+/ISH-）或HER2超低表达（IHC 0）乳腺癌成人患者。

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization [ISH]-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer ...

HER2 classification relies on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), which examines the number of copies of the HER2 gene inside a cancer cell. "On FISH ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Patients with HER2-positive gastric cancer often benefit from ... This test is called immunohistochemistry (IHC) and it just ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

The analysis was performed on independent study sets of HER2-positive and negative/low breast cancers, already analyzed by central immunohistochemistry (IHC) and FISH testing. Phospho-HER2 and ...

T-DXd is also approved for HER2-positive (IHC 3+ or ISH+) breast cancer, non-small cell lung cancer, gastric or gastroesophageal junction cancers, and carries a tumor-agnostic indication for HER2 ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more ... line therapy for HER2+ metastatic gastric cancer, and recent data from the DESTINY ...